Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Comorbidities in Spondyloarthritis

Assessing their incidence worldwide

Publish date:: October 26, 2015

There is a high prevalence of comorbidities associated with spondyloarthritis (SpA), according to a large international study of 3,984 patients with SpA. Researchers found:

• Most frequent comorbidities were osteoporosis (13%), and gastroduodenal ulcer (11%).

• Most frequent risk factors were: hypertension (34%), smoking (29%), hypercholesterolaemia (27%).

• Substantial intercountry variability was seen for screening of comorbidities.

• Systematic evaluation during this study revealed previously unknown risk factors, emphasizing the suboptimal monitoring of comorbidities.

Citation: Molto A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. [Published online ahead of print October 21, 2015]. Ann Rheum Dis. doi: 10.1136/annrheumdis-2015-208174.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Spondyloarthropathies

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,

Novel study explores link between primary immunodeficiencies, rheumatic diseases,

Lower TNF inhibitor efficacy observed in women with nonradiographic axSpA,

Shingrix effective in older adults with preexisting immune-mediated disorders,

Trabecular bone loss may contribute to axial spondyloarthritis progression,